University of Louisville | James Graham Brown Cancer Center

Research site

(Unclaimed)

Location

529 S. Jackson Street, Louisville, Kentucky, United States of America

Site insights

Top conditions

Top treatments

Pembrolizumab

Docetaxel

cisplatin

Oxaliplatin

Ipilimumab

paclitaxel

Cisplatin

Brivanib

SU5416

Irinotecan

Parent organization

This site is a part of University of Louisville

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

12 of 127 total trials

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (CYCLONE 3)

The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse....

Active, not recruiting

Cytochrome P-450

Antineoplastic Agents, Hormonal

Drug: Placebo for Abemaciclib

Drug: Abemaciclib

A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer

Study RGX-104-001 is a Phase 1, first-in-human, dose escalation and expansion study of RGX-104, an oral small molecule targeting the liver X receptor...

Active, not recruiting

Endometrial Cancer

Non-small Cell Carcinoma

Drug: Pembrolizumab

Drug: RGX-104

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

The purpose of this study is to assess the efficacy and safety of lenvatinib (E7080/MK-7902) plus pembrolizumab (MK-3475) plus chemotherapy compared...

Active, not recruiting

Advanced/Metastatic Gastroesophageal Adenocarcinoma

Drug: 5-FU

Biological: Lenvatinib

Locations recently updated

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)

The purpose of this study is to assess the efficacy and safety of pembrolizumab plus lenvatinib plus chemotherapy compared with pembrolizumab plus ch...

Enrolling

Metastatic Esophageal Squamous Cell Carcinoma

Drug: Oxaliplatin

Drug: Levoleucovorin

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizum...

Enrolling

Solid Tumors

Hematologic Malignancies

Drug: Pembrolizumab

Drug: Lenvatinib

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.

Enrolling

Melanoma

Lung Cancer

Biological: OBX-115

Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

This study will evaluate the safety and efficacy of pembrolizumab (MK-3475) versus placebo as adjuvant therapy in participants with hepatocellular ca...

Active, not recruiting

Hepatocellular Carcinoma

Biological: Pembrolizumab

Drug: Placebo

Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301)

This Phase III clinical study will assess the impact of BMN 270 (compared to FVIII prophylaxis) on the number of bleeding episodes irrespective of ex...

Active, not recruiting

Hemophilia A

Biological: valoctocogene roxaparvovec

Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

Prospective, interventional multicenter study evaluating adoptive cell therapy (ACT) via infusion of LN-144 (autologous TIL) followed by interleukin...

Active, not recruiting

Metastatic Melanoma

Biological: Lifileucel

Status recently updated

Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients with Cervical Carcinoma

Prospective, multicenter, single-arm, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymp...

Enrolling

Active, not recruiting

Cervical Carcinoma

Biological: LN-145 + pembrolizumab

Biological: LN-145

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) versus placebo in combination with neoadjuvant (pre-surgery...

Active, not recruiting

Breast Cancer

Biological: Pembrolizumab (K)

Radiation: Radiation therapy

Study of PF-07248144 in Advanced or Metastatic Solid Tumors (KAT6)

This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early...

Enrolling

Locally Advanced or Metastatic Non-small Cell Lung Cancer

Locally Advanced or Metastatic Castration-resistant Prostate Cancer

Drug: PF-07220060

Drug: Fulvestrant